The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Communications and UpdatesFull Access

Differential Effectiveness of Right Unilateral Versus Bilateral Electroconvulsive Therapy in Resistant Bipolar Depression

To the Editor: The article by Helle K. Schoeyen, M.D., Ph.D., et al. (1), published in the January 2015 issue of the Journal, compared electroconvulsive therapy (ECT) with right electrode placement with algorithm-based pharmacotherapy in treatment-resistant bipolar depression. The conclusion was that “the remission rate did not differ between the groups” and “remission rates remained modest regardless of treatment choice.” In order to avoid potential misunderstandings, we feel that the title of the article should have clearly stated that the ECT technique used was exclusively unilateral. Unilateral ECT is known to be less effective—and probably better tolerated—than bilateral ECT (2), and the reported 30% (drug treatment) to 35% (unilateral ECT) remission rates are similar to those found for augmentation strategies in nonbipolar-resistant depression in a real-world setting (3). Furthermore, in the results section, it is clearly apparent that unilateral ECT showed results for higher remission rates that nearly reached statistical significance, compared with algorithm-based drug treatment. Considering that the sample size was not large, suggesting that the study was likely underpowered, caution is needed when making conclusions such as those made in the abstract because they may prompt physicians to disregard ECT as a treatment option, which does not correspond with the available evidence. Before labeling a patient’s symptoms as “treatment-resistant” or “refractory,” months and repeated assays of ineffective drug treatment with drugs of different classes plus augmentation with other treatment methods (antipsychotics, somatic treatments, psychotherapy) is necessary (4, 5). Recent case reports indicate that ECT may abruptly terminate long-persisting psychiatric conditions. ECT is an orphan treatment because there is no marketing supporting it, and it carries some stigma and a bad reputation, which currently is scientifically unjustified. We simply want to emphasize this point in order to pay justice to both treatment options.

From the NESMOS (Neuroscience, Mental Health, and Sensory Organs) Department, Sapienza University, School of Medicine and Psychology, Sant’Andrea Hospital, Rome; and the Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.

Dr. Pacchiarotti has received CME-related honoraria or consulting fees from ADAMED, Janssen-Cilag, and Lundbeck. Dr. Murru has received CME-related honoraria or consulting fees from ADAMED, AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lundbeck, and Otsuka. Dr. Colom has served as an advisor or speaker for Adamed, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Lundbeck, MSD-Merck, Otsuka, Pfizer, Rovi, Sanofi-Aventis, Shire, and Tecnifar, and he has received royalties from Ars Médica, Cambridge University Press, Giovani Fioriti Ed., Igaku-Shoin Ltd., La Esfera de Los Libros, Mayo Ed. & Columna, Medipage, Morales i Torres Ed, Panamericana, and Solal Ed. Prof. Vieta has received research grants and served as a consultant, advisor, or speaker for Alexza, Almirall, AstraZeneca, Bial, Bristol-Myers Squibb, Eli Lilly, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Solvay, Shire, Takeda, and United Biosource Corp., and he has received research funding from the Spanish Ministry of Science and Innovation, the Stanley Medical Research Institute, and the 7th Framework Program of the European Union. Drs. Kotzalidis and Rapinesi report no financial relationships with commercial interests.

References

1 Schoeyen HK, Kessler U, Andreassen OA, et al.: Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry 2014; 172:41–51LinkGoogle Scholar

2 McCormick LM, Brumm MC, Benede AK, et al.: Relative ineffectiveness of ultrabrief right unilateral versus bilateral electroconvulsive therapy in depression. J ECT 2009; 25:238–242Crossref, MedlineGoogle Scholar

3 Trivedi MH, Fava M, Wisniewski SR, et al.: STAR*D Study Team: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243–1252Crossref, MedlineGoogle Scholar

4 Pacchiarotti I, Mazzarini L, Colom F, et al.: Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120:429–440Crossref, MedlineGoogle Scholar

5 Vieta E, Colom F: Therapeutic options in treatment-resistant depression. Ann Med 2011; 43:512–530Crossref, MedlineGoogle Scholar